Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a document filed with the SEC, which is available at this link.

Daniel Bradbury also recently made the following trade(s):

• On Monday, January 6th, Daniel Bradbury sold 7,867 shares of Castle Biosciences stock. The stock was sold at an average price of $29.14, for a total transaction of $229,244.38.

Castle Biosciences Trading Down 0.8 %

Shares of Castle Biosciences stock traded down $0.23 during trading on Friday, hitting $27.60. The stock had a trading volume of 266,866 shares, compared to its average volume of 461,644. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $773.08 million, a PE ratio of 138.01 and a beta of 0.91. The stock has a 50 day simple moving average of $28.26 and a 200 day simple moving average of $28.80. Castle Biosciences, Inc. has a 1 year low of $16.97 and a 1 year high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. During the same period in the previous year, the company earned ($0.26) earnings per share. On average, research analysts expect that Castle Biosciences, Inc. will post 0.38 EPS for the current fiscal year.

Institutional Trading of Castle Biosciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. AlphaQuest LLC lifted its stake in shares of Castle Biosciences by 136.9% in the fourth quarter. AlphaQuest LLC now owns 10,231 shares of the company’s stock worth $273,000 after buying an additional 5,913 shares during the last quarter. Bailard Inc. increased its position in Castle Biosciences by 12.5% during the fourth quarter. Bailard Inc. now owns 9,900 shares of the company’s stock worth $264,000 after acquiring an additional 1,100 shares during the period. Bank of New York Mellon Corp increased its position in Castle Biosciences by 10.3% during the fourth quarter. Bank of New York Mellon Corp now owns 84,459 shares of the company’s stock worth $2,251,000 after acquiring an additional 7,881 shares during the period. Hussman Strategic Advisors Inc. bought a new position in Castle Biosciences during the fourth quarter worth $1,959,000. Finally, New York State Common Retirement Fund increased its position in Castle Biosciences by 2.8% during the fourth quarter. New York State Common Retirement Fund now owns 189,101 shares of the company’s stock worth $5,040,000 after acquiring an additional 5,170 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Scotiabank lifted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 6th. Robert W. Baird boosted their target price on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. BTIG Research upped their target price on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Lake Street Capital upped their price target on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, Stephens reissued an “overweight” rating and set a $41.00 target price on shares of Castle Biosciences in a report on Thursday, January 2nd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.29.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.